Kimberly Gentile compensation by year
Biohaven Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $470,487 | $489,306 | $508,879 |
| Bonus | $370,509 | $385,329 | $228,996 |
| Stock awards | $0 | $0 | $579,600 |
| Option awards | $1,701,221 | $2,945,471 | $2,626,542 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $17,656 | $18,865 | $19,847 |
| Total | $2,559,873 | $3,838,971 | $3,963,864 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Biohaven Ltd. DEF 14A filed March 13, 2026, accession 0001935979-26-000028, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Biohaven Ltd. filed document, accession 0001935979-26-000028. Every figure is read from that document and cited to the page and table it appears in. Filed March 13, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 11,250 | $127,013 | — |
| Option | 19,687 | — | $29.49 |
| Option | 48,124 | — | $41.93 |
| Option | 68,250 | — | $38.64 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Biohaven Ltd.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed March 13, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-15 | Grant or award derivative | — | 1,000 | $0.00 | 1,000 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Biohaven discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $254,440 | $127,013 | $0 | $381,453 |
| Involuntary termination without cause | $254,440 | $0 | $0 | $254,440 |
| Change in control, no termination | $0 | $127,013 | $0 | $127,013 |
| Death | $0 | $0 | $0 | $0 |
| Disability | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Biohaven Ltd.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Biohaven’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Vlad Coric | Chief Executive Officer | $13,500,438 |
| Bruce Car | Chief Scientific Officer | $4,768,188 |
| Matthew Buten | Chief Financial Officer | $4,517,252 |
| Kimberly Gentile · this page | Senior Vice President, Clinical Operations | $3,963,864 |
The full Biohaven compensation record
free company briefThis page is one person within Biohaven's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Biohaven proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Biohaven's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Biohaven's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BHVN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.